Advertisement

Complications in the Cosmetic Use of Botulinum Toxin Type A: Prevention and Management

  • Whitney FlorinEmail author
  • Jacob Haiavy
Chapter

Abstract

Botulinum toxin type A (BTX-A) has become the most frequently requested nonsurgical procedure performed around the world. The use of BTX-A in cosmetics has expanded greatly since its approval by the Food and Drug Administration for reduction of glabellar rhytids. Experienced clinicians have been using BTX-A in other areas off-label to improve the appearance of rhytids and facial harmony. Adverse effects associated with BTX-A are rare and tend to be mild and temporary, such as bruising, swelling, and pain at injection sites. More serious complications, such as brow ptosis or eyelid ptosis, can occur. These complications can be minimized by a thorough understanding of the anatomy of the face and careful injection technique, which will be outlined in this article.

References

  1. 1.
    Qaqish C. Botulinum toxin use in the upper face. Atlas Oral Maxillofacial Surg Clin N Am. 2016;24:95–103.CrossRefGoogle Scholar
  2. 2.
    Carruthers J, Fagien S, Mattarasso SL, et al. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconst Surg. 2004;114:1S–22S.CrossRefPubMedGoogle Scholar
  3. 3.
    Coleman K, Carruthers J. Combination therapy with Botox and fillers: the new rejuvenation paradigm. Dermatol Ther. 2006;19:177–88.CrossRefPubMedGoogle Scholar
  4. 4.
    Carruthers J, Carruthers A. Botulinum toxin in facial rejuvenation: an update. Dermatol Clin. 2009;27(4):417–25.CrossRefPubMedGoogle Scholar
  5. 5.
    American Society of Plastic Surgeons. New statistics reflect the changing face of plastic surgery. https://www.plasticsurgery.org/news/press-releases/new-statistics-reflect-the-changing-face-of-plastic-surgery
  6. 6.
    Tremaine AM, McCullough JL. Botulinum toxin type A for the management of glabellar rhytids. Clin Cosmet Investig Dermatol. 2013;3:15–23.Google Scholar
  7. 7.
    Ramirez-Castaneda J, Jankovic J. Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins. 2013;5(2):249–66.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with C. Botulinum A exotoxin. In: Carruthers J, Carruthers A. Botulinum toxin in facial rejuvenation: an update.Google Scholar
  9. 9.
    Botox Cosmetic OnabotulinumtoxinA: full prescribing information. Allergan Inc. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103000s5236lbl.pdf
  10. 10.
    Xeomin IncobotulinumtoxinA: full prescribing information. Merz Pharmaceuticals, LLC. 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125360lbl.pdf
  11. 11.
    Dysport AbobotulinumtoxinA: full prescribing information. Ipsen Pharmaceuticals and Galderma Laboratories. 2016. https://www.dysport.com/pdfs/Dysport_Full_Prescribing_Information.pdf.
  12. 12.
    Chen JJ, Dashtipour K. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. Pharmacotherapy. 2013;33(3):304–18.CrossRefPubMedGoogle Scholar
  13. 13.
    Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004;22(1):66–75.CrossRefPubMedGoogle Scholar
  14. 14.
    Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type A for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg. 2001;108(1):215–7.CrossRefGoogle Scholar
  15. 15.
    Rzany B, Zielke H. Safety of botulinum toxin in aesthetic medicine. In: Botulinum toxin in aesthetic medicine. Berlin: Springer; 2007. p. 119–25.Google Scholar
  16. 16.
    Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003;29(5):548–56.Google Scholar
  17. 17.
    Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. In: Louis ED, editor. Tremor Other Hyperkinet Mov. 2012;2:tre-02-85-417-1.Google Scholar
  18. 18.
    Matarasso A, Shafer D. Botulinum toxin injections for facial rejuvenation. In: Nahai F, editor. The art of aesthetic surgery: principles and techniques. 2nd ed. St Louis, MO: Quality Medicine Publishing; 2011. p. 243–6. (4 in Qaquish).Google Scholar
  19. 19.
    Sorensen EP, Urman C. Cosmetic complications: rare and serious events following botulinum toxin and soft tissue filler administration. J Drugs Dermatol. 2015;14(5):486–91.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Associate, Inland Cosmetic SurgeryRancho CucamongaUSA
  2. 2.Medical Director, Inland Cosmetic SurgeryRancho CucamongaUSA

Personalised recommendations